GAMMA Investing LLC Raises Holdings in Boston Scientific Corporation $BSX

Key Points

• GAMMA Investing LLC increased its stake in Boston Scientific Corporation by 15.4% during Q2, owning 29,486 shares worth $3.17 million at quarter's end.
• Boston Scientific's quarterly earnings revealed an EPS of $0.75, surpassing analysts' expectations, with revenue up 22.8% year-over-year.
• A significant number of insider sales occurred, with executives selling over 174,000 shares valued at $18.4 million in the last three months.

GAMMA Investing LLC raised its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 15.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 29,486 shares of the medical equipment provider's stock after purchasing an additional 3,932 shares during the period. GAMMA Investing LLC's holdings in Boston Scientific were worth $3,167,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in BSX. Vanguard Group Inc. raised its position in Boston Scientific by 1.3% in the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Boston Scientific by 18.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider's stock valued at $1,070,387,000 after buying an additional 1,664,108 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Boston Scientific by 161.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after acquiring an additional 1,536,663 shares in the last quarter. Swedbank AB raised its position in shares of Boston Scientific by 114.5% during the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider's stock worth $302,816,000 after purchasing an additional 1,505,019 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $133,855,000. Institutional investors own 89.07% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BSX shares. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and increased their price target for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. UBS Group upped their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, July 24th. Leerink Partners initiated coverage on Boston Scientific in a research report on Monday, June 16th. They issued an "outperform" rating and a $118.00 target price on the stock. Truist Financial boosted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Finally, Raymond James Financial lifted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 24th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $118.04.

Boston Scientific Stock Down 0.9%

Shares of BSX stock traded down $0.92 during trading hours on Monday, reaching $96.91. 11,012,552 shares of the stock were exchanged, compared to its average volume of 8,405,870. The firm has a market capitalization of $143.60 billion, a P/E ratio of 57.69, a P/E/G ratio of 2.36 and a beta of 0.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The business's fifty day moving average is $104.25 and its two-hundred day moving average is $102.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 174,214 shares of company stock worth $18,397,457. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.